Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525126 | 0.94 | RAB9A (0.36) | RAB9AALDH1A1HTTNPC1UCHL1 | |
| SCHEMBL2522091 | 0.88 | PYGL (0.37) | RAB9AALDH1A1HTTNPC1UCHL1 | |
| SCHEMBL2523924 | 0.87 | AAK1 (0.38) | — | |
| SCHEMBL2523277 | 0.81 | AAK1 (0.39) | RAB9AALDH1A1HTTKMT2A | |
| SCHEMBL2520920 | 0.79 | ALDH1A1 (0.42) | RAB9AALDH1A1HTTUCHL1ERCC1 | |
| SCHEMBL2518135 | 0.79 | RAB9A (0.41) | RAB9AALDH1A1HTTNPC1FOLH1 | |
| SCHEMBL2522895 | 0.77 | AAK1 (0.40) | RAB9AALDH1A1HTTNPC1UCHL1 | |
| SCHEMBL2517093 | 0.72 | RAB9A (0.43) | RAB9AALDH1A1HTTNPC1TPSAB1 | |
| SCHEMBL2524662 | 0.71 | TSHR (0.43) | RAB9AALDH1A1KMT2AHSP90AA1 | |
| SCHEMBL2524682 | 0.70 | DGAT1 (0.36) | UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251173-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-10-13 | — | — | US | disclosed |
| WO-2011121350-A1 | 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251173-A1 | CHEMICAL COMPOUNDS | DGAT1, DGAT2, SLC5A1 | RAB9A 1067/4885ALDH1A1 410/4885HTT 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.